A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

Lung cancer is the malignant tumor with the highest incidence and mortality rate in the world. With the in-depth research of ...

Prof Patrick Forde of the Trinity St James’s Cancer Institute presented the findings at the latest meeting of the American ...

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer improved long-term ...

Lung cancer patients can expect improved long term survival under a new treatment combination, according to new Irish ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer (NSCLC) - the ...